| 刘 俊,王韡旻,潘 峰.埃克替尼治疗215例复治晚期非小细胞肺癌[J].肿瘤学杂志,2017,23(1):25-29. |
| 埃克替尼治疗215例复治晚期非小细胞肺癌 |
| Efficacy of Icotinib for Patients with Re-treated Advanced Non-small Cell Lung Cancer |
| 投稿时间：2016-07-22 |
| DOI：10.11735/j.issn.1671-170X.2017.01.B005 |
|
 |
| 中文关键词: 埃克替尼 非小细胞肺癌 复治 |
| 英文关键词:icotinib non-small cell lung cancer re-treatment |
| 基金项目: |
|
| 摘要点击次数: 1796 |
| 全文下载次数: 849 |
| 中文摘要: |
| 摘 要：［目的］ 观察盐酸埃克替尼治疗复治晚期非小细胞肺癌（NSCLC）患者的疗效及安全性。［方法］ 对215例复治晚期NSCLC患者应用埃克替尼125mg/次，一日3次，直到疾病进展或者出现不可耐受的不良反应。［结果］ 全组患者达到完全缓解（CR） 2例（0.9%），部分缓解（PR） 75例（34.9%），疾病稳定（SD） 67例（31.2%），疾病进展（PD） 71例（33.0%）。客观缓解率（RR）35.8%，疾病控制率（DCR）67.0%。女性、腺癌、ECOG PS 评分≤1、非吸烟及 EGFR基因突变阳性患者 RR 显著性高于男性、非腺癌、ECOG PS 评分≥2、吸烟及EGFR基因突变未知及野生型患者（P<0.05）。女性、ECOG PS 评分≤1及非吸烟患者 DCR 显著性高于男性、ECOG PS 评分≥2及吸烟患者（P<0.05）。中位无进展时间（mPFS）为 6.8 个月（95%CI：5.9～7.7 个月），中位生存时间（mOS）为 15.5 个月（95%CI：14.0~16.9 个月）。女性、非吸烟、腺癌、ECOG PS 评分≤1及EGFR基因突变阳性患者mPFS明显优于男性、吸烟、非腺癌、ECOG PS 评分≥2及EGFR基因突变未知及野生型患者（P<0.05）。主要不良反应多为Ⅰ～Ⅱ度的皮疹（39.5%）和腹泻（27.4%），大部分患者均可耐受。［结论］ 埃克替尼用于复治NSCLC患者尤其是EGFR基因突变阳性腺癌患者具有较好的疗效，不良反应多可耐受。 |
| 英文摘要: |
| Abstract：［Objective］ To evaluate the curative effect and safety of icotinib in treatment of patients with re-treated advanced non-small cell lung cancer(NSCLC). ［Methods］ Two hundred and fifteen patients with retreated advanced NSCLC received oral icotinib(125mg，3 times per day) until disease progression or unacceptable toxicity. The efficacy and adverse effects were analyzed. ［Results］ There were complete response(CR) in 2 patients（0.9%），partial response(PR) in 75 patients（34.9%），stable disease(SD) in 67 patients（31.2%） and progressive disease(PD) in 71 patients（33.0%）. The recent response rate (RR) and disease control rate (DCR) of the 215 re-treated patients were 35.8% and 67.0%，respectively. The RR was significantly higher in female patients and patients with adenocarcinoma，ECOG PS≤1，non-smoking，EGFR mutation(P<0.05) and DCR was significantly higher in female patients and patients with ECOG PS≤1 and non-smoking(P<0.05). The median progression-free survival (mPFS) was 6.8 months (95%CI:5.9～7.7 months)，the median overall survival (mOS) was 15.5 months(95%CI:14.0～16.9 months). The female patients，and patients with adenocarcinoma，non-smoking，EGFR mutation and lower PS had a longer PFS than male patients，and patients with non-adenocarcinoma，smoking，wild type EGFR and higher PS，respectively(P<0.05). Treatments were generally well tolerated. The main adverse reactions included rash(39.5%) and diarrhea (27.4%). ［Conclusion］ Icotinib had a substantial effect for patients with re-treated advanced NSCLC，especially for adenocarcinoma patients with EGFR mutation，and the toxicities were tolerable. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|